多发性骨髓瘤干细胞移植的现状

Current status of stem cell transplantation for multiple myeloma.

作者信息

Gertz Morie A, Lacy Martha Q, Dispenzieri Angela, Hayman Suzanne

机构信息

Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

Curr Treat Options Oncol. 2005 May;6(3):229-40. doi: 10.1007/s11864-005-0006-1.

DOI:10.1007/s11864-005-0006-1

PMID:15869734

Abstract

Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

摘要

干细胞移植治疗骨髓瘤已成为新诊断患者的标准治疗方法。目前的证据支持对首次移植后未达到完全缓解或非常好的部分缓解（<90%）的患者进行串联移植。移植是安全的，并且已证明即使对于65至70岁的患者也能延长生存期。沙利度胺、来那度胺和硼替佐米等新型药物是否会对干细胞移植的生存优势产生影响尚不清楚。